biotech / news / / Medical Xpress
Yale chemist Craig Crews founded a biotechnology company in New Haven.
Vepdegestrant (Veppanu) is the first PROTAC therapy approved by the FDA for breast cancer.
KEY POINTS
- Vepdegestrant is co-developed by Arvinas and Pfizer for estrogen receptor-positive, ESR1-mutated breast cancer.
- PROTACs, pioneered at Yale, are now positioned for development in diseases beyond cancer, including neurodegeneration.
- Crews’s earlier research led to Kyprolis, an FDA-approved proteasome inhibitor for multiple myeloma.
COMPANIES
Summarized by Newsio from Medical Xpress. How we summarize →